ICER panel says two ALS drug candidates have 'low' long-term value

Paul Schloesser

Associate Editor

ALS is well-known as one of the most difficult drug targets, and the US cost-effectiveness watchdog ICER isn’t quite inching closer to endorsing the two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ICER panel says two ALS drug candidates have 'low' long-term value

Paul Schloesser

Associate Editor

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

ICER pan­el says two ALS drug can­di­dates have 'low' long-term val­ue

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

ICER panel says two ALS drug candidates have 'low' long-term value

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations